CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth
Champions Oncology's first-quarter fiscal 2027 results record revenue and margin growth, stronger adjusted earnings and surging data-license revenues.
Market news
12 items · search:live+archive
News sentiment over time
Daily average lexicon sentiment across 202 scored headlines over the last 8 days. For market-wide mood (VIX, breadth, regime), see Markets. For the learned model that predicts forward return from a headline, see Headline Forecast Model.
Champions Oncology Inc (CSBR) (Q1 2027) Earnings Call Highlights: Data Licensing Surge and ...
Champions Oncology Inc (CSBR) posted 9% revenue growth, 50% gross margin, and record data licensing revenue in Q1 fiscal 2027.
Champions Oncology (CSBR) Q1 2027 Earnings Call Transcript
Data licensing revenue surged past full-year fiscal 2026 totals in single quarter.
Champions Oncology, Inc. Q1 2027 Earnings Call Summary
Moby summary of Champions Oncology, Inc.'s Q1 2027 earnings call
Champions Oncology Q1 Earnings Call Highlights
Champions Oncology (NASDAQ:CSBR) reported first-quarter fiscal 2027 revenue growth, improved margins and its fifth consecutive quarter of positive adjusted EBITDA, as both its translational oncology services and data licensing businesses contributed to results. Revenue for the quarter totaled $15.2
Champions Oncology (NASDAQ:CSBR) Shares Jump as Q1 Margins Expand and Adjusted EBITDA Turns Higher
Champions Oncology Q1 revenue hits $15.2M as margins and adjusted EBITDA jump, sending CSBR shares up 13% after hours.
Champions Oncology Reports Revenue of $15.2 Million
Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000HACKENSACK, NJ / ACCESS Newswire / September 10, 2026 / (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2027, ended July 31, 2026.First Quarter and Recent Highlights: * Revenue of $15.
Champions Oncology Q1 Adj. EPS $0.05 Up From $0.01 YoY, Sales $15.232M Up From $13.995M YoY
Champions Oncology (NASDAQ:CSBR) reported quarterly earnings of $0.05 per share. This is a 400 percent increase over earnings of $0.01 per share from the same period last year. The company reported $15.232 million in
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ended July 31, 2026, on Thursday, September 10, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.
Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging
New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.-based workflowHACKENSACK, NJ / ACCESS Newswire / September 1, 2026 / , a leading provider of translational oncology research solutions, today announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities.
Champions Oncology Expands Radiopharmaceutical Platform With In-House SPECT/CT Imaging For Integrated Tumor Biology And Efficacy Insights
New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.S.-based workflowHACKENSACK, NJ / ACCESS
Diagnostics
sourcesearch:live+archive
count12
archive_hits0
hintWorker/cron → market_news table for the default view; search spans the permanent news_archive plus a live Finnhub top-up